APLT stock forecast
Our latest prediction for Applied Therapeutics Inc's stock price was made on the Sept. 14, 2021 when the stock price was at 14.20$.
In the short term (2weeks), APLT's stock price should outperform the market by 1.36%. During that period the price should oscillate between -10.57% and +12.65%.
In the medium term (3months), APLT's stock price should underperform the market by -5.30%. During that period the price should oscillate between -42.29% and +31.19%.Get email alerts
Create a solid portfolio with APLT
About Applied Therapeutics Inc
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a pivotal Phase 1/2 clinical trial in June 2019, read out positive top-line biomarker data in adult Galactosemia patients in January 2020 and announced full data from the trial in April 2020. A pediatric Galactosemia study commenced in June 2020. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -4.38$ per share.
The book value per share is 4.04$
Three months stock forecastSept. 14, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|